Claims for Patent: 10,100,309

Summary for Patent: 10,100,309

Title:	Targeting the steroidogenic pathway for treating and/or preventing allergic diseases
Abstract:	The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
Inventor(s):	Gelfand; Erwin W. (Cherry Hills Village, CO), Wang; Meiqin (Glendale, CO), Jia; Yi (Centennial, CO)
Assignee:	National Jewish Health (Denver, CO)
Application Number:	15/348,345
Patent Claims:	1. A method of treating an allergic disease in a subject who has, or is at risk of developing an allergic disease, comprising administering to the subject a therapeutically effective amount of a cytochrome P450 family 11 subfamily A polypeptide 1 (Cyp11A1) inhibitor, wherein the inhibitor is a Cyp11A1 shRNA, and wherein the allergic disease is selected from the group consisting of an allergic lung disease, allergen-induced airway hyperresponsiveness, allergen-induced inflammation, asthma, and food allergy. 2. The method of claim 1, wherein the allergic disease is caused by one or more proteinaceous allergens. 3. The method of claim 1, wherein the subject has been sensitized to an allergen or is at risk of becoming exposed to an allergen. 4. The method of claim 1, wherein the food allergy is peanut allergy. 5. The method of claim 1, wherein the allergic disease is an allergic lung disease. 6. A method of inhibiting T-cell pro-allergic differentiation in a subject comprising administering to the subject a therapeutically effective amount of a Cyp11A1 inhibitor, wherein the subject has an allergic disease, and wherein the Cyp11A1 inhibitor is a Cyp11A1 shRNA. 7. The method of claim 6, wherein the T-cell pro-allergic differentiation is CD4+ T-cells to Th2 and Th17 cell differentiation. 8. The method of claim 6, wherein the T-cell pro-allergic differentiation is CD8+ T-cells to Tc2 cell differentiation. 9. The method of claim 6, wherein the T-cell pro-allergic differentiation is IL4-induced conversion of CD8+ T-cells into IL-13 secreting cells. 10. The method of claim 6, wherein the T-cell pro-allergic differentiation is IL-4 induced conversion of CD4+ T-cells into IL-13 secreting cells. 11. The method of claim 6, wherein the allergic disease is selected from the group consisting of a allergic lung disease, allergen-induced airway hyperresponsiveness, allergen-induced inflammation, asthma, and food allergy. 12. The method of claim 11, wherein the allergic disease is caused by one or more proteinaceous allergens. 13. The method of claim 11, wherein the food allergy is peanut allergy. 14. The method of claim 11, wherein the allergic disease is allergic lung disease.

Details for Patent 10,100,309

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020	10,100,309	2036-11-10